CEPI Joint Coordination Group – First Meeting Report
Coalition for Epidemic Preparedness Innovations (CEPI)
The first meeting of the CEPI Joint Coordination Group was held in Geneva November 18, 2016 where members of the JCG and invited observers participated. The attending organizations contributed with expertise and experiences in furtherance of fulfilling the CEPI mission by discussing alignment of activities, and making recommendations for how CEPI can best coordinate vaccine development for EID along the ‘end-to-end’ spectrum.
:: Summary of proceedings
High Level Summary
Inform about the first JCG meeting, which intended to; clarify and discuss roles and responsibilities of the JCG, update stakeholders on CEPIs work and progress, get feedback on how CEPI should proceed and what considerations to take when working in the end-to-end spectrum.
:: More clarity on the regulatory pathway is sought, as fast approval during outbreak is crucial. CEPI should support and facilitate a regulatory harmonization, but not take on a normative or direct coordinating role. Others should fulfil the latter.
:: Funding and shared risks/rewards: Need guarantee for industry that no loss will incur by
engaging. Some point at the necessity for allowing a small profit margin, in particular to ensure
sustainability for smaller biotech companies, even if it might impede accessibility. Others
disagree. Value-based pricing is discussed.
:: To securing a diverse preclinical pipeline, CEPI should focus on what others are not. Focus on
platform technologies and lead head-to head comparisons. Benchmarking is important in several aspects, and standardization and reference labs should therefore be considered.
:: CEPI will play an important role in aligning investments and actors for clinical development and trials. Pull mechanisms, the use of prices and milestone payments should also be considered.
:: In preparedness phase, CEPI could create clinical trial centers of excellence and a network of
investigator sites to build capacity and preparedness in LMIC. Consider doing efficacy trials
outside of outbreaks.
:: Strong national level and community engagement necessary in countries when outbreaks occur. Ethical standards to be upheld.
:: Secure stockpiles for emergency use and containment of outbreak: aligning interest with
procurement agencies will be important. Transparency is necessary for more accurate forecasting of stockpile needs. Consider mechanisms for reserved manufacturing capabilities.
:: Strong appetite for setting up working groups. No objections to reconstituting the JCG into a
smaller and more technical group, possibly also extending with additional meetings.